Sana Q2 net loss $114M ($0.59/shr); cash $325.9M; SC291 enrollment ongoing, data expected H2 2023

Sana Biotechnology, Inc.

2023-Q2 EPS reported -$1.02

Net loss of $114M in Q2 2023 vs $72.5M in Q2 2022; six-month net loss $196.1M.
Cash, cash equivalents, and marketable securities $325.9M as of June 30, 2023, expected to fund operations into 2025.
Enrolling patients in ARDENT Phase 1 trial for SC291 (CD19 CAR T) in B-cell malignancies; initial clinical data expected in H2 2023.
Plan to file IND for SC262 and SG299 in hematologic cancers and SC451 (islet cell) in type 1 diabetes in 2024.
Appointed Doug Williams as President of R&D and Gary Meininger as CMO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.6

Sana Biotechnology, Inc. reported financial results for the quarter and year ended June 30, 2023.

Period: the quarter and year ended June 30, 2023
Result: reported results

Exact text from the filing

On August 3, 2023, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended June 30, 2023.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Sana Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-038002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.